» Articles » PMID: 28785587

Amplification and Mutations in Glioblastoma Patients of the Northeast of Morocco

Abstract

Glioblastomas are the most frequent and aggressive primary brain tumors which are expressing various evolutions, aggressiveness, and prognosis. Thus, the 2007 World Health Organization classification based solely on the histological criteria is no longer sufficient. It should be complemented by molecular analysis for a true histomolecular classification. The new 2016 WHO classification of tumors of the central nervous system uses molecular parameters in addition to histology to reclassify these tumors and reduce the interobserver variability. The aim of this study is to determine the prevalence of mutations and amplifications in the population of the northeast region of Morocco and then to compare the results with other studies. . codon 132 and codon 172 were directly sequenced and the amplification of exon 20 of gene was investigated by qPCR in 65 glioblastoma tumors diagnosed at the University Hospital of Fez between 2010 and 2014. . The R132H mutation was observed in 8 of 65 tumor samples (12.31%). No mutation of was detected. amplification was identified in 17 cases (26.15%). . A systematic search of both histological and molecular markers should be requisite for a good diagnosis and a better management of glioblastomas.

Citing Articles

The Impact of Extensive Surgical Resection of Butterfly Glioblastomas on Outcomes in the Presence of TERT Mutation and EGFR Amplification: A Retrospective Cohort Study.

Hekimoglu M, Basak A, Akgun M, Ozer H, Ozgen U, Maleki R Cancer Control. 2024; 31:10732748241288121.

PMID: 39327682 PMC: 11437567. DOI: 10.1177/10732748241288121.


Glioma lateralization: Focus on the anatomical localization and the distribution of molecular alterations (Review).

Tuncel Cini N, Pennisi M, Genc S, Spandidos D, Falzone L, Mitsias P Oncol Rep. 2024; 52(4).

PMID: 39155859 PMC: 11358673. DOI: 10.3892/or.2024.8798.


Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.

Squalli Houssaini A, Lamrabet S, Nshizirungu J, Senhaji N, Sekal M, Karkouri M Vaccines (Basel). 2024; 12(6).

PMID: 38932383 PMC: 11209492. DOI: 10.3390/vaccines12060655.


Prognostic Value of ATRX and p53 Status in High-Grade Glioma Patients in Morocco.

Squalli Houssaini A, Lamrabet S, Senhaji N, Sekal M, Nshizirungu J, Mahfoudi H Cureus. 2024; 16(3):e56361.

PMID: 38633919 PMC: 11022269. DOI: 10.7759/cureus.56361.


Glioblastoma multiforme: Diagnosis, treatment, and invasion.

Li J, Feng L, Lu Y J Biomed Res. 2022; 37(1):47-58.

PMID: 36403983 PMC: 9898042. DOI: 10.7555/JBR.36.20220156.


References
1.
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

2.
Ghasimi S, Wibom C, Dahlin A, Brannstrom T, Golovleva I, Andersson U . Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. J Neurooncol. 2016; 127(3):483-92. PMC: 4835517. DOI: 10.1007/s11060-016-2066-4. View

3.
Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

4.
Zhang R, Shi Z, Chen H, Chung N, Yin Z, Li K . Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget. 2015; 7(4):5030-41. PMC: 4826263. DOI: 10.18632/oncotarget.5456. View

5.
Chen J, Yao Y, Xu H, Qin Z . Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas. Medicine (Baltimore). 2016; 95(9):e2583. PMC: 4782833. DOI: 10.1097/MD.0000000000002583. View